Today, we announced the presentation of data across our robust rheumatology portfolio at this year’s EULAR - European Alliance of Associations for Rheumatology. See how Amgen is showing up at this year’s meeting with findings in rare and inflammatory diseases. 🔗 https://amgen.ly/4bWARiA #EULAR2024
About us
Amgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing and delivering innovative human therapeutics. This approach begins by using tools like advanced human genetics to unravel the complexities of disease and understand the fundamentals of human biology. Amgen focuses on areas of high unmet medical need and leverages its expertise to strive for solutions that improve health outcomes and dramatically improve people's lives. A biotechnology pioneer since 1980, Amgen has grown to be one of the world's leading independent biotechnology companies, has reached millions of patients around the world and is developing a pipeline of medicines with breakaway potential. For more information, visit www.amgen.com and follow us on www.twitter.com/amgen. See our Community Guidelines: bit.ly/smcgl See our Global Privacy Statement Directory: www.amgen.com/dp Special Advisory: Please be cautious of scam recruitment offers claiming to be from Amgen. Such scams may come from various sources, including fake websites and/or unsolicited emails and seek to obtain personal data or payment from victims by offering jobs that do not exist. Please be advised that Amgen would never ask for payment to progress a job application. When in doubt, please check to see if the position in question is posted on this website before applying. Additionally, please report any suspicious recruiting activity to https://complaint.ic3.gov/ and thank you for your assistance.
- Website
-
http://www.amgen.com
External link for Amgen
- Industry
- Biotechnology Research
- Company size
- 10,001+ employees
- Headquarters
- Thousand Oaks, CA
- Type
- Public Company
- Founded
- 1980
- Specialties
- Biologics, Human therapeutics, and Development of novel products
Locations
Employees at Amgen
Updates
-
Amgen announces positive topline results from its novel Phase 3 trial for treatment of Immunoglobulin G4-related disease (IgG4-RD). This data marks a major milestone and demonstrates significant progress towards improving outcomes for those living with IgG4-RD. Our understanding of IgG4-RD is ever-evolving and today’s news underscores our commitment to advancing science for those living with rare diseases. 🔗 https://amgen.ly/3Xb16x8
-
How can we ensure that patients benefit from the breakthroughs in biotechnology? Amgen CEO Bob Bradway shared his insights at the recent Milken Institute Global Conference, where he discussed how AI and other digital advances can help improve efficiency and overcome the "friction points" that can block patients from getting access to new innovations. "We're excited to leverage digital information to ensure we're getting the right healthcare to the right place for the right patients," he said, adding that "we're in a period that's ripe with the opportunity to tell patients who've lived believing that there are no good therapies available for them, that this has changed and that there are now therapies available."
-
Lights, Camera, Action! Acclaimed actress and producer Gina Torres is taking the stage to spotlight heart health. Motivated by her compelling story of being a caregiver and translator for her parents, who lived with high LDL (“bad”) cholesterol, Gina is collaborating with Amgen and AAFP Foundation to drive awareness, education, and change in the Hispanic community.
Actress and Producer Gina Torres Urges Hispanic Americans to Prioritize Cholesterol Care
wwwext.amgen.com
-
At Amgen, all our voices belong. Embracing our differences allows us to better serve patients, and #PrideMonth serves as a reminder of how important it is to foster an environment where everyone has an equal opportunity to thrive. 🗣️ Hear Amgen employees from around the world share their authentic voices and proudly declare, “I belong.”
-
Amgen delivered another year of strong financial performance. Here are 5 highlights from the 2023 Annual Letter to Shareholders. 🔗 https://amgen.ly/4dUt2vj
-
Our own Ian Thompson sets the stage for #BIO2024 and its potential to drive forward-thinking initiatives that will shape the future of biotechnology. Hear more about our participation at this year’s Biotechnology Innovation Organization convention ⬇️
-
Le désir d’avoir un impact direct auprès des patients est ce qui a poussé Christopher Murawsky, Ph.D. à passer du monde universitaire à l’industrie. Chez Amgen, notre recherche n’a pas uniquement pour but la découverte : nous cherchons à faire une différence dans la vie des patients. 🔗https://lnkd.in/gZ5R5NkH
-
Today, we announced the presentation of new data across our broad oncology portfolio, demonstrating our commitment to innovation for people with difficult-to-treat cancers. Findings will be shared at the American Society of Clinical Oncology (ASCO) Annual Meeting, #ASCO24. 🔗 https://amgen.ly/3UWGxln
-
Before Amgen, Aaron had little experience in biotech. That didn’t stop him from utilizing the skills he picked up during his service to join our team and help drive our mission to serve patients forward. Learn more about his story: https://bit.ly/4aKPy76